Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Journal of Biomolecular Screening

Volumn 11, Issue 5, 2006, Pages 457-468

  Fryknäs, Mårten ^a   Rickardson, Linda ^a   Wickström, Malin ^a   Dhar, Sumeer ^a   Lövborg, Henrik ^a   Gullbo, Joachim ^a   Nygren, Peter ^a   Gustafsson, Mats G ^a   Isaksson, Anders ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Annotated compound library; Drug screening; Microarray; Pathway analysis

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANGIOTENSIN II; CALCIUM; CASPASE 3; CASPASE 7; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPHENYLIODONIUM SALT; DNA FRAGMENT; ENOXIMONE; HYDROGEN PEROXIDE; IMAZODAN; MEPACRINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; OLIGOMYCIN; PAPAVERINE; PENTAMIDINE ISETHIONATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE B; QUAZINONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROTENONE; ZARDAVERINE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOSKELETON; DNA METABOLISM; DNA MICROARRAY; DNA REPAIR; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; FLUOROMETRY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AUTOMATIC DATA PROCESSING; CARCINOMA, SQUAMOUS CELL; CASPASES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIDAZINES; QUINAZOLINES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 33747119918     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106288048     Document Type: Article

References (36)

1. Nygren P: What is cancer chemotherapy? Acta Oncol 2001;40:166-174.
2. Posner BA: High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Curr Opin Drug Discov Devel 2005;8:487-494.
3. Hart CP: Finding the target after screening the phenotype. Drug Discov Today 2005;10:513-519.
4. Root DE, Flaherty SP, Kelley BP, Stockwell BR: Biological mechanism profiling using an annotated compound library. Chem Biol 2003;10:881-892.
5. Kelley BP, Lunn MR, Root DE, Flaherty SP, Martino AM, Stockwell BR: A flexible data analysis tool for chemical genetic screens. Chem Biol 2004;11:1495-1503.
6. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244.
7. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002;62:1139-1147.
8. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, et al: Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 2005;93:483-492.
9. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R: Anticancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 1996;74:888-896.
10. Gullbo J, Lovborg H, Dhar S, Lukinius A, Oberg F, Nilsson K, et al: Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anticancer Drugs 2004;15:45-54.
11. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125-5130.
12. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM: Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
13. Mulcahy RT, Bailey HH, Gipp JJ: Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 1994;34:67-71.
14. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, et al: Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003;63:7900-7906.
15. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K: Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer 1994;58:269-274.
16. Mirski SE, Gerlach JH, Cole SP: Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987;47:2594-2598.
17. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
18. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993;53:3221-3225.
19. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987;47:1297-1301.
20. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT: Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988;27:8861-8869.
21. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, et al: Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 1999;38:10793-10800.
22. Lovborg H, Nygren P, Larsson R: Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 2004;3:521-526.
23. Redmond DE Jr, Zhao JL, Randall JD, Eklund AC, Eusebi LO, Roth RH, et al: Spatiotemporal patterns of gene expression during fetal monkey brain development. Brain Res Dev Brain Res 2003;146:99-106.
24. Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-398.
25. Essayan DM: Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-680.
26. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-3342.
27. Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM, Lerner A: Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 2005;69:473-483.
28. Lerner A, Kim DH, Lee R: The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000;37:39-51.
29. Markovic M, Miljkovic D, Trajkovic V: Regulation of inducible nitric oxide synthase by cAMP-elevating phospho-diesterase inhibitors. Curr Drug Targets Inflamm Allergy 2003;2:63-79.
30. Bruce JI, Straub SV, Yule DI: Crosstalk between cAMP and Ca2+ signaling in non-excitable cells. Cell Calcium 2003;34:431-444.
31. Reshkin SJ, Bellizzi A, Cardone RA, Tommasino M, Casavola V, Paradiso A: Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003;9:2366-2373.
32. Stork PJ, Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12:258-266.
33. Ahn YH, Jung JM, Hong SH: 8-Chloro-cyclic AMP-induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells. Cancer Res 2005;65:4896-4901.
34. MacKenzie SJ, Houslay MD: Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J 2000;347:571-578.
35. Shimizu K, Murata T, Okumura K, Manganiello VC, Tagawa T: Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells. Anticancer Drugs 2002;13:875-880.
36. Marko D, Romanakis K, Zankl H, Furstenberger G, Steinbauer B, Eisenbrand G: Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem Biophys 1998;28:75-101.